JP2024522368A - ステープルペプチドおよびその方法 - Google Patents

ステープルペプチドおよびその方法 Download PDF

Info

Publication number
JP2024522368A
JP2024522368A JP2023575560A JP2023575560A JP2024522368A JP 2024522368 A JP2024522368 A JP 2024522368A JP 2023575560 A JP2023575560 A JP 2023575560A JP 2023575560 A JP2023575560 A JP 2023575560A JP 2024522368 A JP2024522368 A JP 2024522368A
Authority
JP
Japan
Prior art keywords
agent
group
amino acid
independently
staple
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522368A5 (https=
Inventor
ブライアン ハルバート ホワイト，
ダニエル スンダク ラ，
ロレンツォ ジョズエ アルファロ－ロペス，
ポーラ クリスティーナ オルテット，
サラ イザベル カプッチ，
ジー リー，
ジョン ハニー マギー，
マーティン ロバート トレンブレイ，
グレゴリー エル． ヴァーダイン，
ヤグアン シー，
ケビン リン，
ペイチェン ドゥ，
ジョナサン バリー フロブ，
Original Assignee
フォグ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォグ ファーマシューティカルズ， インコーポレイテッド filed Critical フォグ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024522368A publication Critical patent/JP2024522368A/ja
Publication of JP2024522368A5 publication Critical patent/JP2024522368A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023575560A 2021-06-08 2022-06-08 ステープルペプチドおよびその方法 Pending JP2024522368A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163208487P 2021-06-08 2021-06-08
US63/208,487 2021-06-08
US202163224834P 2021-07-22 2021-07-22
US63/224,834 2021-07-22
US202263303952P 2022-01-27 2022-01-27
US63/303,952 2022-01-27
PCT/US2022/032738 WO2022261257A1 (en) 2021-06-08 2022-06-08 Stapled peptides and methods thereof

Publications (2)

Publication Number Publication Date
JP2024522368A true JP2024522368A (ja) 2024-06-18
JP2024522368A5 JP2024522368A5 (https=) 2025-06-17

Family

ID=84425507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575560A Pending JP2024522368A (ja) 2021-06-08 2022-06-08 ステープルペプチドおよびその方法

Country Status (9)

Country Link
US (1) US20240360179A1 (https=)
EP (1) EP4355350A4 (https=)
JP (1) JP2024522368A (https=)
KR (1) KR20240031957A (https=)
BR (1) BR112023025528A2 (https=)
CA (1) CA3218824A1 (https=)
IL (1) IL308790A (https=)
MX (1) MX2023014679A (https=)
WO (1) WO2022261257A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
WO2024130217A1 (en) * 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
CN120529912A (zh) * 2022-12-15 2025-08-22 帕拉比利斯药物公司 订书钉化肽及其方法
WO2024130224A2 (en) * 2022-12-16 2024-06-20 Purdue Research Foundation Stapled peptides for sensitization of cancer to treatment
KR20260035134A (ko) * 2023-06-06 2026-03-12 파라빌리스 메디슨즈 인코포레이티드 스테이플화 펩티드 및 이의 방법
WO2025265097A1 (en) * 2024-06-20 2025-12-26 Parabilis Medicines, Inc. Stapled peptides and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549951A3 (en) * 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
WO2016085280A1 (ko) * 2014-11-28 2016-06-02 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US10011631B2 (en) * 2015-12-01 2018-07-03 The University Of Hong Kong Stapled helical peptides and methods of synthesis
AU2018329956A1 (en) * 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
CN117567639A (zh) * 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
MX2021001943A (es) * 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
AU2021314310A1 (en) * 2020-07-22 2023-03-16 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
CA3218824A1 (en) 2022-12-15
US20240360179A1 (en) 2024-10-31
KR20240031957A (ko) 2024-03-08
IL308790A (en) 2024-01-01
BR112023025528A2 (pt) 2024-02-27
EP4355350A1 (en) 2024-04-24
WO2022261257A1 (en) 2022-12-15
MX2023014679A (es) 2024-01-15
EP4355350A4 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
JP2024522368A (ja) ステープルペプチドおよびその方法
JP2023535026A (ja) ステープルペプチドおよびその方法
ES2934810T3 (es) Moléculas químicas que inhiben el mecanismo de empalme para tratar enfermedades causadas por anomalías de empalme
JP6885999B2 (ja) 水溶性プロドラッグ
US10961216B2 (en) Small molecule modulators of the androgen receptor
JP7793506B2 (ja) Ｃｄ３８に結合する薬剤およびその使用
Hu et al. Discovery of highly potent and efficient CBP/p300 degraders with strong in vivo antitumor activity
Wang et al. Diphenylaminothiophen-derived fluorescent ligands targeting mitochondrial DNA G-quadruplexes potentially for triple-negative breast cancer therapy
Abdel-Rahman et al. Lithocholic acid derivatives as potent modulators of the nuclear receptor RORγt
CN115697415A (zh) 用于预防或治疗感染的技术
JP2025541246A (ja) ステープルペプチドおよびその方法
JP2025541247A (ja) ステープルペプチドおよびその方法
CN117794560A (zh) 订书钉化肽及其方法
HK40108355A (zh) 订书钉化肽及其方法
US9714265B2 (en) Mutagenic nucleoside analogs and uses thereof
HK40129655A (zh) 订书钉化肽及其方法
HK40128981A (zh) 订书钉化肽及其方法
WO2022092295A1 (ja) βストランド型架橋ペプチド
WO2025265097A1 (en) Stapled peptides and methods thereof
KR20260035134A (ko) 스테이플화 펩티드 및 이의 방법
CN103570688B (zh) 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
US10273240B2 (en) Cortistatin analogues, syntheses, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250609